Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.

Date publication

mai 2024

Journal

Cancer medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry , Dr DESMOULINS Isabelle , Dr HENNEQUIN Audrey

Tous les auteurs :
Petit T, Hajjaji N, Antoine EC, Benderra MA, Gozy M, Foa C, Mouysset JL, Grenier J, Mousseau M, Mailliez A, Saghatchian M, Lachaier E, Desmoulins I, Hennequin A, Maes P, Loirat D, Ricci F, Diéras V, Berton D, Tiong FL, Teixeira L, Dohollou N, Lévy C, Bachelot T, Pierga JY

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38733172

Résumé

Early access program (formerly cohort Temporary Authorization for Use) was granted for trastuzumab deruxtecan (T-DXd) in France based on DESTINY-Breast01 trial which demonstrated its efficacy and safety in HER2-positive metastatic/unresectable breast cancer after ≥2 anti-HER2-based regimens received at metastatic stage.

Mots clés

HER2‐positive, breast cancer, early‐access program, metastatic cancer, trastuzumab deruxtecan

Référence

Cancer Med. 2024 05;13(9):e7168